

Revision of the framework for interaction with industry and related documents


Maria Filancia, Senior liaison specialist

18th ISG meeting (21/09/2026)



Background

4th December 2014 Industry stakeholders roundtable meeting



- The roundtable discussion with Industry stakeholder organisations: EFPIA, AESGP, Vaccine Europe, EBE, EGA, IFAH, EGGVP, EuropaBio, EUCOPE, Europarm SMC.
- All welcomed the opportunity to discuss further the Industry stakeholder’s eligibility criteria;
- Raised the need to include as eligibility criteria the “non-profit”.
- Raised the need for transparency and publication of the EMA Industry stakeholders list.

➤ On the 5th of October 2015, the Management Board [endorsed](#) the proposal of a framework aimed at “facilitating and streamlining communication, structured interaction, accountability, transparency and a broad representation of the industry.

Evolution of the interaction

✓ Completed action arising from framework annex 1.



Already active fora

- PhV platform
- SME support
- CP platform
- Ad hoc meetings



Eligibility

From 10 to 40! ✓
Involvement in industry and multi-stakeholder activities



Monitoring

- Centralised Procedure ✓
- Supporting innovation
- Engagement/communication
- Biennial reports




Industry webpage



Network

Experience shared with national competent authorities and other EU Agencies. ✓



Main amendments

Key principles related to the scope, objective, methodology and eligibility criteria remain valid.



Framework

- Inclusion of medical device industry, Industry Standing Group and possibility of engagement with senior leaders of pharmaceutical companies.
- Removal of obsolete references and Annex 1.
- Addition of clarifications on engagement with eligible and non-eligible stakeholders.
- Editorial/stylistic improvements.



Eligibility criteria

- Inclusion of medical device industry.
- Addition of clarifications on engagement with eligible and non-eligible stakeholders.
- Editorial/ stylistic improvements.



Application form

- Addition of clarifications on the engagement and requirements.
- Editorial/ stylistic improvements.

Timelines



December 2026: Management Board approval and publication.

Publication of revised framework and eligibility criteria on pharmaceutical industry corporate webpage and dissemination of information via targeted mailing and EMA Industry highlights newsletter.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Thank you

emaindustryliason@ema.europa.eu

Follow us

